RELATED CONTENT
NEWS
- Pfizer's arthritis contender tofacitinib faces possible US approval delay
- Expanded Japanese approval clears way to earlier stage Humira use
- Genentech's Actemra monotherapy beats Abbott's Humira for RA signs and symptoms
- The House that JAK Built: how Pfizer's Xeljanz is poised to take the rheumatoid arthritis crown

